公司概覽
業務類別 Biotechnology
業務概覽 Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
公司地址 50 Northern Avenue, Boston, MA, USA, 02210
電話號碼 +1 617 341-6100
傳真號碼 --
公司網頁 https://www.vrtx.com
員工數量 6400
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Amit K. Sachdev, J.D. Executive Vice President and Chief Patient and External Affairs Officer 美元 700.00K 13/02/2026
Mr. Charles F. Wagner, Jr Executive Vice President, Chief Operating Officer and Chief Financial Officer 美元 974.81K 01/09/2026
Mr. Jonathan Poole Senior Vice President, Finance -- 01/09/2026
Dr. Reshma Kewalramani, M.D. Director, President and Chief Executive Officer 美元 1.60M 02/04/2026
Mr. Jonathan Biller Executive Vice President and Chief Legal Officer -- 13/02/2026
Dr. Ourania Tatsis, PhD Executive Vice President and Chief Regulatory and Quality Officer -- 13/02/2026
Dr. Carmen Bozic, M.D. Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer 美元 835.00K 13/02/2026
Ms. Kristen C. Ambrose Senior Vice President and Chief Accounting Officer -- 13/02/2026
Dr. E Morrow Atkinson, III, PhD Executive Vice President, Chief Technical Operations Officer and Head, Biopharmaceutical Science and Manufacturing Operations -- 13/02/2026
Mr. Duncan J. McKechnie Executive Vice President and Chief Commercial Officer -- 13/02/2026
Mr. Mark E. Bunnage, D.Phil. Executive Vice President and Chief Scientific Officer -- 13/02/2026
 
董事會成員
董事會 職務 更新日期
Mr. Bruce I. Sachs Lead Independent Director 02/04/2026
Mr. Lloyd A. Carney Independent Director 02/04/2026
Dr. Jeffrey M Leiden, PhD Executive Chairman of the Board 02/04/2026
Dr. Alan M. Garber, M.D.,PhD Independent Director 02/04/2026
Mr. Michel Lagarde Independent Director 02/04/2026
Dr. Sangeeta N. Bhatia, PhD Independent Director 02/04/2026
Ms. Diana L. McKenzie Independent Director 02/04/2026
Dr. Reshma Kewalramani, M.D. Director, President and Chief Executive Officer 02/04/2026
Dr. Jennifer Schneider, M.D. Independent Director 02/04/2026
Ms. Nancy A. Thornberry Independent Director 02/04/2026
Mr. Daniel Brennan Director 20/10/2026
 
所屬ETF (更新日期: 14/11/2026 02:02)
代號 名稱 佔比% ▼ 持有日期
GIBPrudential Gibraltar0.002%30/09/2026
MLRGiShares MSCI USA ETF0.002%30/10/2026
BFLXiShares Flexible Equity Active ETF0.002%30/10/2026
DSPYTema S&P 500 Hist Wght ETF Strat0.002%30/10/2026
EPSWisdomTree U.S. LargeCap Fund0.002%30/10/2026
QQXTFirst Trust NASDAQ-100 ex-Tech Sect ETF0.002%29/10/2026
JUSAJPMorgan U.S. Research Enh Lg Cp ETF0.002%30/10/2026
KOMPStt Strt®SPDR®S&PKenshoNwEcosComposETF0.002%30/10/2026
SDGiShares MSCI Global Sust Dev Goals ETF0.002%30/10/2026
CVLCCalvert US Large-Cp Cor Rspnb ETF0.002%30/10/2026
KLMTInvesco MSCI Global Climate 500 ETF0.002%30/10/2026
PSEPInnovator US Equity Power Buffer ETF-Sep0.002%30/10/2026
STXFStrive 500 ETF0.002%30/10/2026
CGVVCapital Group U.S. Large Value ETF0.002%31/10/2026
LSTLeuthold Select Industries ETF0.002%30/10/2026
NTSXWisdomTree U.S. Efficient Core Fund0.002%30/10/2026
VOTETCW Transform 500 ETF0.002%30/10/2026
POCTInnovator U.S. Equity Power Buf ETF™ Oct0.002%30/10/2026
QQQHNEOS Nasdaq-100 Hdg Eq Inc ETF0.002%30/10/2026
GSWOGoldman Sachs ActiveBeta World Eq ETF0.002%30/10/2026
  1    2    3    4    5    6    7    8    9   10    11    12    13    14    15    16    17    18    19    20    21    22    23    24    25  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.